Bik Wojciech, Wolinska-Witort Ewa, Pawlak Joanna, Skwarlo-Sonta Krystyna, Chmielowska Magdalena, Martynska Lidia, Baranowska-Bik Agnieszka, Baranowska Boguslawa
Neuroendocrinology Department, Medical Centre of Postgraduate Education, Marymoncka 99, 01-813 Warsaw, Poland.
J Neuroimmunol. 2006 Aug;177(1-2):76-84. doi: 10.1016/j.jneuroim.2006.04.013. Epub 2006 Jun 23.
The effect of PACAP 38 administration on neuroendocrine and immune parameters was examined in rats with LPS-induced peritonitis. Treatment with PACAP 38 alone did not influence the serum level of the cytokines and hormones examined, but significantly decreased immune cell activity. When administered together with LPS, PACAP 38 reversed its effect on immune and humoral parameters, causing a decrease in the serum concentrations of TNFalpha and corticosterone, and an increase in T4 and GH. The majority of PACAP 38 effects disappeared earlier than those previously observed for VIP. PACAP 38 appears to represent a short-lasting modulator of immune and endocrine responses during acute inflammation.
